A SOFTWARE APPLICATION FOR PREDICTING ALZHEIMER'S DISEASE BASED ON THE LEVEL OF GENE EXPRESSION

Author(s):  
Sofiia Yefremova ◽  

This article discusses the process of creating a software application that predicts Alzheimer's disease based on gene expression data in healthy and sick patients. The object of the study is the expression samples of genes taken from the study, which used the side of the middle temporal gyrus of the brain of frozen samples.

2020 ◽  
Vol 127 ◽  
pp. 124-135
Author(s):  
George D. Vavougios ◽  
Christiane Nday ◽  
Sygliti-Henrietta Pelidou ◽  
Sotirios G. Zarogiannis ◽  
Konstantinos I. Gourgoulianis ◽  
...  

RSC Advances ◽  
2016 ◽  
Vol 6 (100) ◽  
pp. 98080-98090 ◽  
Author(s):  
Hongbo Xie ◽  
Haixia Wen ◽  
Mingze Qin ◽  
Jie Xia ◽  
Denan Zhang ◽  
...  

We provided a computational drug repositioning method for the treatment of Alzheimer's disease.


2021 ◽  
Author(s):  
Hamed Taheri Gorji ◽  
Ramtin Kardan ◽  
Neda Rezagholizadeh

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder and the most commonly diagnosed cause of dementia, and it is the fifth leading cause of death among people aged 65 and older. During the years, the early diagnosis of AD patients has been a significant concern for researchers, in view of the fact that early diagnosis not only can lead to saving lives of the AD patients but also could bring a considerable amount of saving in health and long-term care expenditures for both people and the government. Mild cognitive impairment (MCI), defined as a transitional state between being healthy and having AD, is considered an established risk factor for AD. Hence, an accurate and reliable diagnosis of MCI and, consequently, discrimination between healthy people, MCI individuals, and AD patients can play a crucial role in the early diagnosis of AD. In recent years, analysis of blood gene expression data has been grabbed more attention than the conventional AD diagnosis method because it provides the opportunity to investigate the biochemical pathways, cellular functions, and regulatory mechanisms for finding the key genes associated with MCI and AD. Therefore, in this study, we employed blood gene expression data from Alzheimer's Disease Neuroimaging Initiative (ADNI), two feature selection methods for determining the most prominent genes related to MCI and AD, and three classifiers for the most accurate discrimination between three groups of healthy, MCI and AD. The proposed method yielded the selection of top ten genes from more than 49,000 genes and the best overall classification result between healthy and AD patients with average values of the area under the curve (AUC) of 0.77 +- 0.08. Furthermore, gene ontology (GO) analysis revealed that four genes were enriched with the GO terms of regulation of cell proliferation, negative regulation of cell population proliferation, signaling receptor binding, biological adhesion, and cytokine production.


2020 ◽  
Author(s):  
Shahan Mamoor

We sought to understand, at the systems level and in an unbiased fashion, how gene expression was most different in the brains of patients with Alzheimer’s Disease (AD) by mining published microarray datasets (1, 2). Comparing global gene expression profiles between patient and control revealed that a set of 84 genes were expressed at significantly different levels in the middle temporal gyrus (MTG) of patients with Alzheimer’s Disease (1, 2). We used computational analyses to classify these genes into known pathways and existing gene sets, and to describe the major differences in the epigenetic marks at the genomic loci of these genes. While a portion of these genes is computationally cognizable as part of a set of genes up-regulated in the brains of patients with AD (3), many other genes in the gene set identified here have not previously been studied in association with AD. Transcriptional repression, both pre- and post-transcription appears to be affected; nearly 40% of these genes are transcriptional targets of MicroRNA-19A/B (miR-19A/B), the zinc finger protein 10 (ZNF10), or of the AP-1 repressor jun dimerization protein 2 (JDP2).


Sign in / Sign up

Export Citation Format

Share Document